HR Execs on the Move

Federation Bio

www.federation.bio

 
Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies. The company`s first-in-class platform combines the power of genetic engineering and synthetic consortium design to control systemic immune responses and broad metabolic functions. Federation Bio`s pipeline addresses a range of serious illnesses from metabolic disorders to metastatic cancer. The company`s lead program is in enteric hyperoxaluria, a serious renal condition that affects more than 250,000 Americans and for which there are currently no approved therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.federation.bio
  • 300 Utah Avenue Suite 100
    South San Francisco, CA USA 94080
  • Phone: 650.434.8282

Executives

Name Title Contact Details

Similar Companies

World Views Spatial Technologi

World Views Spatial Technologi is a Barrington, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Axiom Real-time Metrics

Axiom Real-time Metrics is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Icon Genetics

Icon Genetics is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pear Therapeutics

Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions and is the leader in FDA-authorized prescription digital therapeutics.

Adgero Biopharmaceuticals

Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.